MyFinsight
Home
Blog
About
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Change in fair value of warrant ...
Other current assets
Accounts payable and accrued lia...
Others
Negative Cash Flow Breakdown
Change in fair value of derivati...
Prepaid expenses
Effect of foreign currency trans...
Proceeds from exercises of pre-f...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Change in fair value of warrant liabilities
-
-
0
-46,870
Loss on asset write-off
0
-
-
-
Impairment expense
-
-
4,162,911
-
Depreciation
0
-
0
24,051
Realized foreign currency translation loss from dissolution of subsidiaries
0
-
-7,171
-
Net loss
-5,273,852
-2,869,482
-10,110,868
-3,037,420
Amortization expense
157,541
157,541
157,541
157,541
Stock-based compensation
329,940
139,182
88,277
52,987
Realized foreign currency translation loss from dissolution of subsidiaries
-
-
-
0
Change in fair value of derivative warrant liability
-
-
416,619
-
Change in fair value of warrant liabilities
1,527,603
-1,542,132
-
-
Loss on asset disposal
-
-
0
102,913
Change in fair value of derivative warrant liability
-1,548,227
-
-
-
Prepaid expenses
626,882
1,018,063
-474,553
-15,696
Other current assets
-377,929
12,647
379,158
-84,777
Accounts payable and accrued liabilities
348,432
358,381
-206,697
-243,700
Net cash used in operating activities
-4,707,516
-4,787,220
-5,396,822
-2,890,025
Proceeds from may 2025 public offering of common stock, net
-
-
4,214,506
-
Proceeds from sale of common stock under atm agreement, net
0
-
-2,136,158
2,203,724
Proceeds from the sale of equipment
-
-
11,000
-
Proceeds from sale of common stock from public offerings, net
0
-
53,413,572
-2,203,724
Net cash provided by investing activities
-
-
11,000
-
Proceeds from exercises of warrants
0
-
969,000
0
Payments on financed director and officer insurance
0
-
39,310
116,145
Proceeds from exercises of pre-funded warrants
-750
750
0
0
Issuance of common stock from the exercise of warrants, net
9,226
-
-
-
Net cash provided by financing activities
8,476
750
56,421,610
-116,145
Effect of foreign currency translation on cash
-37,328
28,132
465
12,670
Net change in cash, cash equivalents, and restricted cash
-4,736,368
-4,758,338
51,036,253
-2,993,500
Cash, cash equivalents, and restricted cash - beginning of period
50,501,467
55,259,805
4,223,552
6,922,729
Cash, cash equivalents, and restricted cash - end of period
45,765,099
50,501,467
55,259,805
4,223,552
Cash and cash equivalents
45,663,782
-
-
-
Restricted cash
101,317
-
-
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of common stock
from the exercise of...
$9,226
Net cash provided by
financing activities
$8,476
(-99.88%↓ Y/Y)
Canceled cashflow
$750
Net change in cash,
cash equivalents,...
-$4,736,368
(-1709.24%↓ Y/Y)
Canceled cashflow
$8,476
Change in fair value of
warrant liabilities
$1,527,603
(2332.33%↑ Y/Y)
Other current assets
-$377,929
(-1405.51%↓ Y/Y)
Accounts payable and
accrued liabilities
$348,432
(-24.52%↓ Y/Y)
Stock-based compensation
$329,940
(111.23%↑ Y/Y)
Amortization expense
$157,541
(-50.00%↓ Y/Y)
Proceeds from exercises
of pre-funded...
-$750
(-186.11%↓ Y/Y)
Net cash used in
operating activities
-$4,707,516
(32.02%↑ Y/Y)
Effect of foreign
currency translation on...
-$37,328
(-762.90%↓ Y/Y)
Canceled cashflow
$2,741,445
Net loss
-$5,273,852
(27.55%↑ Y/Y)
Change in fair value of
derivative warrant...
-$1,548,227
Prepaid expenses
$626,882
(13.82%↑ Y/Y)
Buy us a coffee